Guided Therapeutics Q2 net loss narrows 29.44% to $604,000; revenue drops to no revenue

PUBT · 1d ago
Guided Therapeutics Q2 net loss narrows 29.44% to $604,000; revenue drops to no revenue
  • Guided Therapeutics posted a net loss attributable to common stockholders of USD 604,000 in Q2 2026, narrowing from USD 856,000 a year earlier.
  • Revenue was nil, versus USD 117,000 a year earlier; deferred revenue totaled USD 189,000 on advance customer payments.
  • R&D expense fell 74.4% to USD 34,000 on lower clinical research costs after completing FDA-related clinical trials.
  • General and administrative expense dropped 35.7% to USD 423,000, partly due to the prior-year warrant compensation charge for Dr. Mark Faupel.
  • FDA clinical results were filed in June 2026; China NMPA inspection is targeted for Q3 2026, with approval possible in Q4 2026 or Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guided Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-004958), on August 13, 2026, and is solely responsible for the information contained therein.